Anxiety and substance use don’t just overlap by coincidence. According to SAMHSA’s 2022 National Survey on Drug Use and Health, which surveyed over 67,500 adults, roughly 21.5 million Americans live with a co-occurring mental health and substance use disorder, and anxiety disorders are among the most common mental health conditions found alongside addiction. If that pattern sounds familiar in your own life or someone you love, understanding the biology behind it changes everything about how to approach treatment.
Why anxiety and substance use almost always show up together
A 2020 SAMHSA report analyzing data from the National Survey on Drug Use and Health found that adults with anxiety disorders were two to three times more likely to develop a substance use disorder compared to those without a mental health diagnosis. The report drew from a nationally representative sample of more than 56,000 respondents. The finding holds across age groups, genders, and substance types.
What this means in practice is that the connection between anxiety and substance use isn’t a character flaw or a coincidence. It’s a documented biological and behavioral pattern. Anxiety activates the brain’s threat-detection system continuously, flooding the body with stress hormones and producing physical symptoms that feel unbearable: a pounding heart, shallow breathing, a mind that won’t stop cycling through worst-case scenarios. Substances interrupt that process fast. The brain notices, and it remembers. That’s not weakness. That’s neuroscience.
How anxiety drives people toward substances
A 2019 study published in JAMA Psychiatry, drawing on data from 43,000 adults in the National Epidemiologic Survey on Alcohol and Related Conditions, found that self-medication of anxiety symptoms was one of the strongest predictors of developing an alcohol use disorder. Participants who reported drinking specifically to manage fear, nervousness, or worry were significantly more likely to meet diagnostic criteria for alcohol dependence within three years.
The mechanism is straightforward. Anxiety produces a state of sustained discomfort that the nervous system is wired to escape. Substances provide fast, reliable relief. The brain is a pattern-learning machine, and when a behavior reliably reduces pain, it stores that behavior as a solution. Over time, reaching for alcohol, opioids, cannabis, or benzodiazepines when anxiety spikes stops being a choice and starts being an automatic response.
The practical takeaway at this stage is simple but powerful: identifying the specific relief pattern, meaning the moment anxiety peaks and substance use follows, is the first step to interrupting it. You don’t have to stop the behavior before you understand it. Start by noticing it.
The relief that becomes the problem
A 2018 study published in the journal Alcohol and Alcoholism examined how alcohol affects amygdala activity, the brain region responsible for processing fear and threat. Researchers found that acute alcohol use suppresses amygdala reactivity, which is why a drink produces a genuine calming effect. But with repeated use, the amygdala becomes hypersensitive as a compensatory response. The baseline anxiety level rises. The same amount of alcohol produces less relief than it did before.
This is the experience many people describe without having words for it: calmer at night, more anxious by morning. The substance that once worked stops working, but the anxiety it was managing is now worse than when it started. The cycle is biological, not personal.
The action here is concrete: track your anxiety levels for one week, morning and evening, alongside your substance use. Before assuming the substance is still helping, the data from your own life will tell you whether it’s actually making things worse.
Which substances people with anxiety reach for most
SAMHSA’s 2021 Treatment Episode Data Set, which captures intake information from publicly funded treatment programs across the country, shows that alcohol is the most commonly reported primary substance among adults entering treatment with a co-occurring anxiety disorder, followed by opioids and cannabis. Benzodiazepines, while less prevalent in raw numbers, appear disproportionately among people with panic disorder and generalized anxiety disorder specifically.
Each substance targets a different part of the brain’s anxiety circuitry. Alcohol and benzodiazepines both enhance GABA, the brain’s main inhibitory neurotransmitter, producing sedation and reduced arousal. Cannabis temporarily reduces activity in the prefrontal cortex, quieting the rumination and catastrophizing that define many anxiety disorders. Opioids activate the brain’s reward and pain-suppression systems, providing relief that extends beyond physical pain into emotional distress.
The practical value of knowing this isn’t academic. Recognizing which substance you or someone you care about is using, and why, helps clinicians design a more targeted treatment plan. The specific substance-anxiety pairing tells a story about which symptoms were being managed, and that story guides treatment.
How substances make anxiety worse over time
A 2021 study in Neuropsychopharmacology followed 380 adults with co-occurring anxiety and substance use disorders over 24 months and documented a process called anxiety sensitization: chronic substance use progressively lowers the brain’s tolerance for stress, so that everyday situations trigger increasingly severe anxiety responses. The brain’s stress-response system, particularly the HPA axis governing cortisol release, becomes dysregulated with sustained use, and this dysregulation persists into early abstinence.
In plain terms: the more you use to manage anxiety, the more anxious your brain becomes at baseline. The dose that once produced calm now barely takes the edge off, but stopping produces an anxiety response that feels more intense than anything experienced before substance use began. That escalation is not imagined. It’s a documented neurological shift, and it’s one of the clearest signs that dependence has developed.
Understanding this reframes a common mistake. If anxiety is getting worse despite continued use, the instinct to use more is the wrong one. Increasing anxiety during active use is a signal of dependence, not a reason to increase the dose.
Withdrawal anxiety: why stopping feels impossible
A 2020 NIDA-funded review published in Biological Psychiatry synthesized data from 40 clinical studies and found that anxiety symptoms during withdrawal are one of the primary drivers of relapse in the first 30 days of abstinence. Withdrawal-induced anxiety can include panic attacks, hyperventilation, racing heart, insomnia, and a pervasive sense of dread that feels identical to severe generalized anxiety disorder.
This is the point where the two conditions become impossible to separate without clinical support. Withdrawal anxiety and anxiety disorder anxiety feel the same to the person experiencing them, which makes it nearly impossible to assess the underlying mental health condition accurately until the acute withdrawal period has passed. That’s exactly why medically supervised detox matters, not just for physical safety, but for clinical accuracy.
Withdrawal anxiety is temporary and treatable. It peaks within the first week for most substances and diminishes significantly within two to four weeks with proper support. You don’t have to manage it alone, and you don’t have to white-knuckle through it to prove something.
The cycle that keeps people stuck
A 2022 study published in the Journal of Substance Abuse Treatment, following 1,200 adults through SUD treatment programs over 18 months, found that participants with untreated co-occurring anxiety disorders relapsed at nearly double the rate of those whose anxiety was addressed during treatment. The study noted that anxiety symptoms were the most frequently reported trigger for relapse, cited more often than cravings, social pressure, or life stressors.
The cycle is worth naming precisely because it feels inescapable from inside it: anxiety produces discomfort, substance use produces relief, relief is followed by rebound anxiety (often worse than before), which produces more use, which deepens dependence, which raises baseline anxiety, which makes the next episode harder to manage. The clinical term for this pattern is a co-occurring disorder, sometimes called a dual diagnosis. The terminology matters less than the insight it carries: treating only one side of the cycle leaves the other side intact, and the intact side will pull the person back in.
If this cycle sounds familiar, the treatment approach has to address both conditions at the same time. Treating the addiction without addressing the anxiety, or managing the anxiety without addressing the substance use, leaves half the problem in place. For those in Western Maryland, understanding what integrated mental health and addiction care looks like is the starting point.
What dual diagnosis treatment actually means
A 2019 SAMHSA report titled “Substance Use Disorders and Mental Health” reviewed outcomes data from integrated treatment programs and found that patients receiving simultaneous treatment for co-occurring SUD and mental health disorders had significantly better outcomes at 12 months than those treated sequentially, meaning addiction first, then mental health, or vice versa. Retention in treatment was 30% higher in integrated programs, and self-reported anxiety symptoms were substantially lower at discharge.
Dual diagnosis treatment, also called integrated treatment, means one clinical team managing both conditions under one coordinated plan. Not a referral to a separate therapist for anxiety after discharge. Not addressing the mental health piece “later.” One intake, one treatment team, one plan that holds both the substance use and the anxiety as equally important and interconnected.
In practice, that looks like addiction treatment where the clinical team understands anxiety, screens for it at intake, and builds it into every element of care, from individual therapy to group sessions to medication management. If a program only treats one condition and expects the other to resolve on its own, that’s a sign the program isn’t built for the complexity of your situation.
Types of anxiety disorders most commonly treated alongside substance use
According to NIDA’s 2021 research summary on comorbidity, the anxiety disorders most frequently diagnosed alongside substance use disorders are generalized anxiety disorder (GAD), social anxiety disorder, panic disorder, and post-traumatic stress disorder (PTSD). Each has a distinct presentation, and each responds to somewhat different treatment strategies, which is why accurate diagnosis at intake matters.
GAD is characterized by persistent, excessive worry across multiple areas of life, often including health, finances, and relationships, with physical symptoms like muscle tension and sleep disruption. Social anxiety disorder centers on intense fear of judgment or humiliation in social situations, which frequently drives alcohol use in social contexts. Panic disorder involves recurring, sudden episodes of extreme fear with physical symptoms that can feel like a heart attack. PTSD, while technically classified separately from anxiety disorders in current diagnostic criteria, involves persistent hyperarousal and avoidance that overlaps substantially with anxiety and is extremely common in people seeking treatment for trauma alongside addiction.
Knowing the name of the anxiety condition isn’t about labeling yourself. It’s about being able to advocate for yourself at intake and ensuring the treatment plan is specific to what you’re actually experiencing.
Evidence-based treatments that work for both conditions
A 2021 meta-analysis published in JAMA Psychiatry, synthesizing data from 37 randomized controlled trials involving more than 5,000 participants, found that cognitive behavioral therapy (CBT) produced significant reductions in both substance use and anxiety symptoms when the treatment was adapted to address both conditions simultaneously. The effect sizes were larger in integrated CBT protocols than in those treating either condition alone.
CBT works by identifying the thought patterns and behavioral responses that sustain both anxiety and substance use, and systematically replacing them with more accurate thinking and healthier coping behaviors. In sessions, this looks like mapping out the specific triggers, thoughts, feelings, and behaviors that connect anxiety to substance use, then practicing alternative responses. Exposure therapy, a specific form of CBT, is particularly effective for social anxiety disorder and panic disorder, gradually reducing the fear response through structured, supported exposure to feared situations.
Medication-assisted treatment (MAT) is often part of integrated care as well, particularly for opioid use disorder and alcohol use disorder. Ask any prospective treatment program directly whether they offer CBT specifically adapted for co-occurring conditions, not generic talk therapy, but structured, evidence-based CBT targeting both anxiety and substance use.
What medication-assisted treatment looks like for co-occurring anxiety
A 2020 study published in Drug and Alcohol Dependence followed 620 adults receiving MAT for opioid use disorder and found that participants who also received pharmacological treatment for co-occurring anxiety, through non-addictive medications such as SSRIs or SNRIs, had significantly better retention in MAT programs and lower anxiety scores at six months compared to those receiving MAT alone.
Buprenorphine and naltrexone, both FDA-approved for opioid use disorder, do not treat anxiety directly, but stabilizing the physical dependence gives the brain the neurological space it needs for anxiety treatment to be effective. SSRIs and SNRIs, the first-line pharmacological treatments for most anxiety disorders, are non-habit-forming and do not interact problematically with MAT medications in most clinical scenarios.
The concern that medication is “just trading one substance for another” is one of the most persistent and damaging misconceptions in addiction treatment. FDA-approved MAT medications are not addictive in the clinical sense: they don’t produce euphoria at therapeutic doses, they don’t escalate, and they treat a documented neurological condition. Ask the prescribing clinician specifically how anxiety symptoms will be managed during MAT, and expect a concrete answer.
What to expect during anxiety and substance use treatment in washington county, MD
For adults in Hagerstown and the surrounding Washington County area seeking anxiety and substance abuse treatment, the general pathway begins with a screening and intake evaluation where both the substance use history and the mental health history are assessed together. If physical dependence is present, medically supervised detox may be the first step, followed by an appropriate level of outpatient or residential programming. The treatment plan is built from the intake findings, not applied generically.
Maryland Medicaid covers substance use disorder treatment, including dual diagnosis programs, under the state’s behavioral health managed care system. Major commercial insurers operating in this area, including Aetna, CareFirst, Cigna, and Optum, are required under the Mental Health Parity and Addiction Equity Act to cover behavioral health treatment at the same level as medical care. Cost is not an automatic barrier to starting treatment. The first call is to confirm what your specific plan covers, not to assume it doesn’t.
Levels of care available in the hagerstown and washington county area
The continuum of care in Washington County includes standard outpatient services, intensive outpatient programs (IOP), partial hospitalization programs (PHP), and inpatient or residential treatment. Each level differs primarily in the number of clinical hours per week and the degree of structure provided.
Outpatient treatment typically involves one to three sessions per week and suits people with stable housing, strong support systems, and moderate symptom severity. Intensive outpatient programs run three to five days per week for several hours per day, providing substantial structure while allowing the person to live at home. Partial hospitalization programs are the most intensive outpatient option, often meeting five to six days per week for six or more hours daily, and are appropriate for people who need significant clinical support but don’t require 24-hour supervision. Inpatient or residential treatment provides round-the-clock care and is typically indicated when safety is a concern or when the level of medical complexity warrants it.
The clinician conducting your intake determines the appropriate level of care based on the severity of both conditions. Your job is to show up and be fully honest about both the anxiety symptoms and the substance use. Minimizing either one affects the accuracy of the placement decision.
Insurance coverage for co-occurring disorder treatment in maryland
The Mental Health Parity and Addiction Equity Act, enforced at the federal level and reinforced by Maryland state law, requires that insurance plans covering mental health and substance use treatment do so at parity with medical and surgical coverage. According to the Maryland Insurance Administration, violations of parity law are actively investigated and insurers cannot impose higher copays, lower visit limits, or more restrictive prior authorization requirements for behavioral health than for comparable medical services.
In practice, this means Aetna, CareFirst, Cigna, Optum, and Maryland Medicaid are all required to cover dual diagnosis treatment that is clinically determined to be medically necessary. The process for confirming coverage is straightforward: call the member services number on the back of your insurance card and ask specifically about co-occurring disorder benefits, including both the mental health and substance use components. Don’t assume the cost is out of reach before you make that call. For more detail on what co-occurring disorder treatment in this area involves, the specifics are worth understanding before your intake.
The biggest myths about anxiety and substance use treatment
The first and most persistent myth is that treating the addiction will make the anxiety go away on its own. A 2020 study published in the Journal of Anxiety Disorders followed 890 adults through SUD treatment programs and found that anxiety symptoms persisted at clinically significant levels in 60% of participants at six months post-discharge when anxiety was not directly treated during the program. Anxiety disorders are neurobiological conditions with their own treatment requirements. Sobriety alone does not resolve them.
The second myth is that any medication used in mental health treatment is “just another addiction.” The clinical distinction is clear: medications prescribed for anxiety, including SSRIs, SNRIs, and non-addictive anxiolytics like buspirone, do not produce dependence, don’t require escalating doses to maintain effect, and are supported by decades of randomized controlled trial evidence. The fear is understandable given the history with benzodiazepines, but conflating all psychiatric medication with addiction reflects a misunderstanding of pharmacology, not a reasonable caution.
The third myth is that lifelong anxiety is untreatable. A 2019 meta-analysis in Psychological Medicine reviewed 130 randomized trials covering CBT for generalized anxiety disorder and found response rates above 60% for CBT alone, with even higher rates for combined medication and therapy approaches. Anxiety disorders are among the most treatment-responsive psychiatric conditions that exist. The fact that anxiety has been present for a long time doesn’t mean it can’t be treated. It means it hasn’t been treated yet.
A fourth misconception worth addressing directly: that disclosing anxiety symptoms at a substance use intake will somehow complicate or delay treatment. The opposite is true. Programs built on dual diagnosis treatment principles need the full clinical picture to build an effective plan. Withholding either condition weakens the plan from the start.
What happens if only one condition gets treated
A 2023 study in JAMA Network Open, drawing from a sample of 2,800 adults across 14 outpatient SUD treatment programs, found that participants with untreated co-occurring anxiety disorders were 1.9 times more likely to relapse within 12 months compared to those who received integrated treatment. The researchers identified unmanaged anxiety as the single strongest predictor of early relapse, ahead of social isolation, housing instability, and prior treatment history.
The reverse is equally true. Treating anxiety without addressing the substance use produces limited results because the neurological changes driven by active addiction interfere directly with the brain’s capacity to respond to anxiety treatment. The substance disrupts sleep, destabilizes mood, and blunts the emotional processing that therapy depends on. Both conditions need to be on the table at the same time.
At any intake appointment, disclose both the anxiety symptoms and the substance use in full detail. What feels like oversharing is actually the information a clinician needs to build a plan that works. A program not equipped to address both isn’t the right program, and knowing that early saves time. For those navigating the specific overlap of PTSD and substance use, understanding what comprehensive recovery looks like for that combination is worth exploring alongside this.
What to try this week
Call one treatment provider in the Hagerstown or Washington County area and name both concerns at the start of the conversation: anxiety and substance use. Not one or the other. Both. Ask directly whether the program treats co-occurring disorders in an integrated model, meaning both conditions addressed within the same program by the same team, not referred out separately.
Before the call, confirm your coverage. Check the member services number on your Aetna, CareFirst, Cigna, or Optum card, or your Maryland Medicaid documentation, and ask specifically about co-occurring disorder benefits. Insurance coverage is not a reason to delay this call.
The anxiety and the substance use are connected. Treatment that addresses only one leaves the connection intact, and that connection is what drives the cycle. The call takes ten minutes. Make it this week.
Frequently asked questions
What is dual diagnosis treatment and is it available in washington county, MD?
Dual diagnosis treatment means treating a substance use disorder and a co-occurring mental health condition, such as anxiety, at the same time within one coordinated program. It is available in the Hagerstown and Washington County area through programs that screen for both conditions at intake and address both in the treatment plan. If you’re unsure whether a program offers this, ask directly during your first call: “Do you treat anxiety and substance use together in one program?”
Does maryland medicaid cover anxiety and substance use treatment together?
Yes. Maryland Medicaid covers behavioral health treatment including co-occurring disorder programs. Under the state’s behavioral health managed care system, substance use and mental health services are covered when clinically determined to be medically necessary. Contact your Medicaid managed care organization directly to confirm your specific benefits before assuming coverage is unavailable.
How do I know if my anxiety is making my substance use worse?
A reliable indicator is the escalation pattern: if anxiety symptoms are increasing despite continued or increasing substance use, and if stopping or reducing use produces anxiety that feels more severe than the original problem, that’s a sign the substance use and the anxiety are feeding each other. A clinical evaluation at an integrated treatment program can assess this accurately during intake.
Can anxiety be treated effectively at the same time as addiction?
Yes. The research is clear on this point: integrated treatment that addresses both conditions simultaneously produces better outcomes than treating either condition alone or in sequence. CBT adapted for co-occurring conditions, combined with appropriate medication management where indicated, is the evidence-based standard of care.
What if i’ve had anxiety my whole life and assumed it couldn’t be treated?
Longstanding anxiety is treatable. Duration doesn’t determine treatability. A 2019 meta-analysis in Psychological Medicine covering 130 randomized trials found CBT response rates above 60% for generalized anxiety disorder alone, with higher rates when medication is added. The more accurate statement is that the anxiety hasn’t been treated yet in a way that was effective, not that it can’t be treated at all.
Will admitting to anxiety symptoms at a substance use intake complicate my treatment?
No. Disclosing both conditions at intake is the most useful thing you can do for your own treatment outcome. Programs that specialize in co-occurring disorders are built to address this complexity. Withholding anxiety symptoms from a substance use intake, or substance use from a mental health intake, results in a treatment plan built on incomplete information. The full picture is what makes the plan work.
